Skip to search formSkip to main contentSkip to account menu

aclidinium

Known as: (3-Carbamoyl-3,3-diphenylpropyl)ethyldimethylammonium 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta… 
Highly Cited
2017
Highly Cited
2017
The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of… 
2016
2016
Background Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of… 
Review
2015
Review
2015
The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive… 
Review
2014
Review
2014
BACKGROUND Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving… 
Highly Cited
2013
Highly Cited
2013
Abstract Background: This randomized, double-blind, Phase IIIb study evaluated the 24-hour bronchodilatory efficacy of aclidinium… 
2013
2013
Background and ObjectivesAclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance… 
Highly Cited
2011
Highly Cited
2011
Background Fibroblast to myofibroblast transition is believed to contribute to airway remodelling in lung diseases such as asthma… 
Highly Cited
2010
Highly Cited
2010
Mucus hypersecretion and mucin MUC5AC overexpression are pathological features of chronic obstructive pulmonary disease (COPD… 
Review
2008
Review
2008
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with…